Cargando…
Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study
Cetuximab improves efficacy when added to chemotherapy for metastatic colorectal cancer (mCRC). Effective management of skin reactions from cetuximab improves quality of life (QoL), and treatment compliance in clinical trials. No data are available from real‐world settings. The ObservEr observationa...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119983/ https://www.ncbi.nlm.nih.gov/pubmed/27748041 http://dx.doi.org/10.1002/cam4.888 |
_version_ | 1782469153801633792 |
---|---|
author | Pinto, Carmine Di Fabio, Francesca Rosati, Gerardo Lolli, Ivan R. Ruggeri, Enzo M. Ciuffreda, Libero Ferrari, Daris Lo Re, Giovanni Rosti, Giovanni Tralongo, Paolo Ferrara, Raimondo Alabiso, Oscar Chiara, Silvana Ianniello, Giovanni P. Frassoldati, Antonio Bilancia, Domenico Campanella, Giovanna A. Signorelli, Carlo Racca, Patrizia Benincasa, Elena Stroppolo, Maria Elena Di Costanzo, Francesco |
author_facet | Pinto, Carmine Di Fabio, Francesca Rosati, Gerardo Lolli, Ivan R. Ruggeri, Enzo M. Ciuffreda, Libero Ferrari, Daris Lo Re, Giovanni Rosti, Giovanni Tralongo, Paolo Ferrara, Raimondo Alabiso, Oscar Chiara, Silvana Ianniello, Giovanni P. Frassoldati, Antonio Bilancia, Domenico Campanella, Giovanna A. Signorelli, Carlo Racca, Patrizia Benincasa, Elena Stroppolo, Maria Elena Di Costanzo, Francesco |
author_sort | Pinto, Carmine |
collection | PubMed |
description | Cetuximab improves efficacy when added to chemotherapy for metastatic colorectal cancer (mCRC). Effective management of skin reactions from cetuximab improves quality of life (QoL), and treatment compliance in clinical trials. No data are available from real‐world settings. The ObservEr observational, multicenter, prospective study evaluated QoL, the incidence of skin reactions, and management of chemotherapy plus cetuximab in first‐line for mCRC. The primary endpoint was QoL measured with the Dermatology Life Quality Index (DLQI) and EORTC QLQ‐C30. Secondary endpoints were the incidence of skin and serious adverse events, median overall and progression‐free survival, tumor response, and resection rates. Between May 2011 and November 2012, 228 patients with KRASwt mCRC were enrolled at 28 Italian centers, 225 evaluable, median age 65 years. QoL did not change during treatment and was not affected by the choice of prophylactic or reactive skin management. The incidence of cetuximab‐specific grade ≥3 skin reactions was 14%, with no grade 4/5 events. Skin reactions correlated with survival (P = 0.016), and their incidence was influenced by chemotherapy regimen (oxaliplatin vs. irinotecan—Incidence rate ratio [IRR] 1.72, P < 0.0001) and gender (male vs. female—IRR 1.38, P = 0.0008). Compliance at first postbaseline evaluation was 97.75%. Median overall survival was 23.6 months, median progression‐free survival 8.3 months. Cetuximab plus chemotherapy did not compromise QoL in the routine clinical setting when patients receive close monitoring plus prophylactic or reactive management of skin reactions. We observed the same correlation between overall survival (OS) and skin reactions reported in controlled clinical trials, also in this setting. |
format | Online Article Text |
id | pubmed-5119983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-51199832016-11-28 Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study Pinto, Carmine Di Fabio, Francesca Rosati, Gerardo Lolli, Ivan R. Ruggeri, Enzo M. Ciuffreda, Libero Ferrari, Daris Lo Re, Giovanni Rosti, Giovanni Tralongo, Paolo Ferrara, Raimondo Alabiso, Oscar Chiara, Silvana Ianniello, Giovanni P. Frassoldati, Antonio Bilancia, Domenico Campanella, Giovanna A. Signorelli, Carlo Racca, Patrizia Benincasa, Elena Stroppolo, Maria Elena Di Costanzo, Francesco Cancer Med Cancer Prevention Cetuximab improves efficacy when added to chemotherapy for metastatic colorectal cancer (mCRC). Effective management of skin reactions from cetuximab improves quality of life (QoL), and treatment compliance in clinical trials. No data are available from real‐world settings. The ObservEr observational, multicenter, prospective study evaluated QoL, the incidence of skin reactions, and management of chemotherapy plus cetuximab in first‐line for mCRC. The primary endpoint was QoL measured with the Dermatology Life Quality Index (DLQI) and EORTC QLQ‐C30. Secondary endpoints were the incidence of skin and serious adverse events, median overall and progression‐free survival, tumor response, and resection rates. Between May 2011 and November 2012, 228 patients with KRASwt mCRC were enrolled at 28 Italian centers, 225 evaluable, median age 65 years. QoL did not change during treatment and was not affected by the choice of prophylactic or reactive skin management. The incidence of cetuximab‐specific grade ≥3 skin reactions was 14%, with no grade 4/5 events. Skin reactions correlated with survival (P = 0.016), and their incidence was influenced by chemotherapy regimen (oxaliplatin vs. irinotecan—Incidence rate ratio [IRR] 1.72, P < 0.0001) and gender (male vs. female—IRR 1.38, P = 0.0008). Compliance at first postbaseline evaluation was 97.75%. Median overall survival was 23.6 months, median progression‐free survival 8.3 months. Cetuximab plus chemotherapy did not compromise QoL in the routine clinical setting when patients receive close monitoring plus prophylactic or reactive management of skin reactions. We observed the same correlation between overall survival (OS) and skin reactions reported in controlled clinical trials, also in this setting. John Wiley and Sons Inc. 2016-10-17 /pmc/articles/PMC5119983/ /pubmed/27748041 http://dx.doi.org/10.1002/cam4.888 Text en © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Prevention Pinto, Carmine Di Fabio, Francesca Rosati, Gerardo Lolli, Ivan R. Ruggeri, Enzo M. Ciuffreda, Libero Ferrari, Daris Lo Re, Giovanni Rosti, Giovanni Tralongo, Paolo Ferrara, Raimondo Alabiso, Oscar Chiara, Silvana Ianniello, Giovanni P. Frassoldati, Antonio Bilancia, Domenico Campanella, Giovanna A. Signorelli, Carlo Racca, Patrizia Benincasa, Elena Stroppolo, Maria Elena Di Costanzo, Francesco Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study |
title | Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study |
title_full | Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study |
title_fullStr | Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study |
title_full_unstemmed | Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study |
title_short | Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study |
title_sort | observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in kras wild‐type metastatic colorectal cancer patients: the observer study |
topic | Cancer Prevention |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119983/ https://www.ncbi.nlm.nih.gov/pubmed/27748041 http://dx.doi.org/10.1002/cam4.888 |
work_keys_str_mv | AT pintocarmine observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT difabiofrancesca observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT rosatigerardo observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT lolliivanr observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT ruggerienzom observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT ciuffredalibero observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT ferraridaris observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT loregiovanni observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT rostigiovanni observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT tralongopaolo observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT ferrararaimondo observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT alabisooscar observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT chiarasilvana observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT ianniellogiovannip observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT frassoldatiantonio observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT bilanciadomenico observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT campanellagiovannaa observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT signorellicarlo observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT raccapatrizia observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT benincasaelena observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT stroppolomariaelena observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy AT dicostanzofrancesco observationalstudyonqualityoflifesafetyandeffectivenessoffirstlinecetuximabpluschemotherapyinkraswildtypemetastaticcolorectalcancerpatientstheobserverstudy |